Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

• Status: Completed
• Trial end date: 2018-02-07
• Target enrollment: 0
• Participant gender: All

Summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gilead Sciences
• Treatments: Sofosbuvir; Sofosbuvir-velpatasvir drug combination; Velpatasvir

Criteria

Key Inclusion Criteria:

• Willing and able to provide written informed consent

• HCV RNA detected at screening

• Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy

• Classification as treatment naïve or treatment experienced. Approximately 20% may be treatment-experienced.

• Cirrhosis determination (approximately 20% may have cirrhosis)

• Females of childbearing potential must have a negative urine pregnancy test at Screening and on Day 1 prior to enrollment.

• Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in the study protocol

• Lactating females must agree to discontinue nursing before the study drug is administered

• Adults must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments

Key Exclusion Criteria:

• Current or prior history of any of the following:

• Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol

• Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage)

• Liver transplantation

• Hepatocellular carcinoma (HCC) (as determined by appropriate imaging at screening for those with cirrhosis) or current malignancy for which the patient is receiving treatment or which may interfere with individual's treatment, assessment or compliance with the protocol.

• Screening laboratory parameters outside of defined threshold

• Prior exposure to HCV NS5A inhibitor

• Pregnant or nursing female

• Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

• Use of any prohibited concomitant medications as described in study protocol

• Known hypersensitivity to VEL, SOF, or formulation excipients

Note: Other protocol defined Inclusion/Exclusion criteria may apply.